REDWOOD CITY, Calif.--(BUSINESS WIRE)--Prenuvo, a leader in proactive whole-body MRI screening, today announced the appointment of Jill Woodworth as Chief Financial Officer. A seasoned financial executive with deep experience leading high-growth companies through IPO and beyond, Woodworth will lead Prenuvo's financial strategy, operations, and long-term planning as the company enters its next phase of growth. Woodworth is best known for her role as Chief Financial Officer at Peloton, where she.

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 26, 2025 lead plaintiff deadline. SO WHAT: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that screening has been reinitiated in the Company's CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment of type 1 diabetes (T1D).

Despite tariffs and economic uncertainty, customers have not yet changed their spending behaviors, the company said.

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.

Thanks to mounting legal pressure in the United States and China, DA Davidson's Gil Luria gave Alphabet (NASDAQ: GOOGL) stock an unorthodox and conditional price target on May 13.

GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.

NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Take-Two Interactive Software, Inc. ("Take-Two" or "the Company") (NASDAQ:TTWO). Investors who purchased Take-Two securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TTWO.

Belite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is encouraging, but assumptions of success are risky given the small STGD1 market and lack of robust clinical data. Belite's $2bn valuation appears to price in success for both STGD1 and GA, yet GA efficacy data is lacking and competition is fierce.

I maintain a buy rating on The Brink's Co. (BCO) due to strong growth outlook, driven by AMS and DRS segments, and solid 1Q25 results. BCO reported 5.6% organic revenue growth in 1Q25, with broad-based regional momentum and improved margins, reinforcing my positive outlook. AMS and DRS segments showed >20% organic growth, now accounting for 25% of revenue, with significant potential for further expansion and high incremental margins.

Centrais Elétricas Brasileiras S.A. - Eletrobrás (NYSE:EBR ) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Ivan de Souza Monteiro – President Eduardo Haiama – Executive Vice President, Finance and Investor Relations Elio Wolff – Vice President, Strategy and Business Development Rodrigo Limp – Vice President, Regulation and Institutional Relations Conference Call Participants Bruno Amorim – Goldman Sachs Andre Sampaio – Santander Arthur Pereira – J.P.

Birkenstock Holding plc (NYSE:BIRK ) Q2 2025 Results Conference Call May 15, 2025 8:00 AM ET Company Participants Megan Kulick - Director, Investor Relations Oliver Reichert - Director and Chief Executive Officer Ivica Krolo - Chief Financial Officer David Kahan - President, Americas Nico Bouyakhf - President, EMEA Alexander Hoff - Vice President, Global Finance Klaus Baumann - Chief Sales Officer Conference Call Participants Matthew Boss - JPMorgan Simeon Siegel - BMO Mark Altschwager - Baird Dana Telsey - Telsey Group Laurent Vasilescu - BNP Paribas Jay Sole - UBS Lorraine Hutchinson - Bank of America Sam Poser - Williams …

I reiterate my strong buy rating on Dr. Reddy's Laboratories due to its attractive valuation and underappreciated growth potential beyond Revlimid. Recent results exceeded expectations, with 20% YoY revenue growth driven by acquisitions and strong performance in generics, especially in Europe and India. While Revlimid's patent expiry poses a headwind, RDY's robust pipeline in biosimilars and GLP-1s should offset revenue declines and support long-term growth.

Canadian Solar Inc. (NASDAQ:CSIQ ) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ET Company Participants Wina Huang - Head of IR Shawn Qu - Chairman and CEO Yan Zhuang - President of CSI Solar Ismael Guerrero - Corporate VP and President of Recurrent Energy Xinbo Zhu - SVP and CFO Conference Call Participants Colin Rusch - Oppenheimer & Company Philip Shen - Roth Capital Partners Tyler Bisset - Goldman Sachs Alan Lau - Jefferies Praneeth Satish - Wells Fargo Operator Ladies and gentlemen, thank you for standing by. Welcome to Canadian Solar's First Quarter 2025 Earnings Call.

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148701&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Open Lending Corporation (NASDAQ:LPRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/open-lending-corporation-lawsuit-submission-form?prid=148702&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your SoundHound AI, Inc. (NASDAQ:SOUN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/soundhound-ai-inc-lawsuit-submission-form?prid=148703&wire=1&utm_campaign=24 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of EchoStar Corporation ("EchoStar Corporation") (NASDAQ:SATS) concerning possible violations of federal securities laws. The Wall Street Journal reported on May 12, 2025, that the Federal Communications Commission had notified EchoStar that it would be investigating the Company's compliance with federal requirements to build a nationwide 5G network.

Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter the idiopathic hypersomnia market after a favorable court ruling. Analysts remain bullish, reiterating Buy ratings and projecting significant revenue and profit growth through FY2026 as LUMRYZ adoption accelerates.

Uber Technologies (NYSE:UBER ) Annual JPMorgan Global Technology, Media and Communications Conference May 15, 2025 9:20 AM ET Company Participants Dara Khosrowshahi - CEO Conference Call Participants Doug Anmuth - JPMorgan Doug Anmuth All right, we're going to go ahead and get started. I'm Doug Anmuth, JP Morgan's Internet Analyst.